U.S., Sept. 19 -- ClinicalTrials.gov registry received information related to the study (NCT07827768) titled 'Phase 2 Study of AV-1959R in Individuals With Preclinical Alzheimer's Disease' on Sept. 14.
Brief Summary: This Phase 2 study will evaluate the safety, tolerability, immunogenicity, and amyloid-lowering effect of AV-1959R in cognitively unimpaired adults with preclinical Alzheimer's disease. Approximately 160 participants will be randomized to receive AV-1959R or placebo and will be followed for 78 weeks. The study will assess safety, immune responses, brain amyloid, and Alzheimer's disease-related biomarkers.
Study Start Date: March 01, 2027
Study Type: INTERVENTIONAL
Condition:
Preclinical Alzheimer's Disease
Alzheimer Diseas...